Speakers

Expand/Collapse

Lance Weed
Vice President Operations
uniQure

Lance Weed has more than 30 years of extensive experience in the design, construction, process development, manufacturing and establishment of operations for biopharmaceutical facilities including drug substance and drug product lines where no prior manufacturing capability was established. This includes uniQure’s multiproduct gene therapy facility utilizing 100% disposable process systems for drug substance and drug product. Lance also built BioVex’s oncolytic virus production facility which is currently the commercial production facility for Imlygic under Amgen’s ownership. Lance has a degree in Chemical Engineering from University of New Hampshire.

Day Two

Thursday 13th December 2018

12:40 pm | Panel: The Case For and Against Internalizing the Manufacturing Process

Anton Xavier
Founder
K9 Biotech

Anton Xavier is the Founder CEO of K9 Biotech, a pre-clinical comparative oncology venture focused on treating homologous cancers in pet dogs and humans. Anton Xavier is also an Assistant Director at the NY State Center for Biotechnology where he focuses on the development and implementation of technology and business development strategies that will increase sponsored research, company formation, strategic alliances, and investment with external partners in NY State. Prior to founding K9 Biotech, Anton was with Pfizer where he had duties within the External Science and Innovation group (ES&I) focusing on sourcing, screening, and evaluating early through to late stage (inter)national biopharma ventures, entrepreneurial academic PI technology, private/public/local government funded life science initiatives, and funding vehicles which aligned with Pfizer’s R&D interest for investment and strategic partnerships. Additionally, Anton led efforts within Pfizer R&D from discovery through to late stage development of targeted therapeutics for oncology indications. Prior to Pfizer, Anton’s experience was within a wider field of bioscience, including regenerative medicine, infectious disease, and cardiovascular biology where he developed multiple therapeutic, platform, and diagnostic innovations for military and industrial needs.

Day One

Thursday 13th December 2018

11:30 am | Case Study: Comparative Oncology in Domesticated Canines and Humans

9:20 am | Panel: To IT or to IV? Intra-Tumoural vs Intra-Venous Administration

Michael Wood MBA
Founder and Chief Operating Officer
OncoMyx

Michael Wood is Founder & COO at OncoMyx Therapeutics, Inc.. Michael initially trained as a scientist with research roles at the Salk Institute, University of California (UC) Berkeley/Howard Hughes Medical Institute (HHMI) and UC San Francisco. He began his business career as an investment banker and management consultant, then he rotated through sales, marketing and business development in Big Pharma, and subsequently he worked in business development and operational roles of increasing responsibility at both public and private biotech companies. Most recently, he helped orchestrate a $40M series A and led company operations at Crinetics Pharmaceuticals (NASDAQ: CRNX). He earned a BS in Molecular & Cell Biology from UC Berkeley and MBA from the University of Chicago.

Day One

Thursday 13th December 2018

2:40 pm | OncoMyx’s Systemic Administration of EV2

Robert Coffin
CEO
Replimmune

Dr. Robert Coffin MD Co-Founded BioVex Group, Inc., and served as its Chief Scientific Officer since 1999. Mr. Astley-Sparke served as Chief Technology Officer of BioVex, Inc. Dr. Coffin was a founding scientist and Lecturer in Virology and Gene Therapy at University College London and Honorary Senior Lecturer at The Institute of Child Health. He is an expert in the application of virus-based technology to the development of therapeutic products and vaccines, has authored more than 50 scientific papers and is a named inventor on all of the patents filed in BioVex name. He served as Director of BioVex Group, Inc. Dr. Coffin received his PhD in 1991 from Imperial College, London, following which he moved to University College London where he ultimately led the research group.

Day One

Thursday 13th December 2018

8:40 am | Panel: One Vision for the Future of Oncolytic Virotherapies

Daniel Katzman
CEO
Unleash Immuno Oncolytics

Daniel has 20+ years of experience in biotech and drug development. He is a serial entrepreneur with experience in fund-raising, business development and clinical development both in Israel and the USA. Daniel is the Founder and President of NeuroHealing Pharmaceuticals, a biotech company based in Boston and a Venture Partner Biotechnology in Axia Ventures Company Builder.

Day One

Thursday 13th December 2018

2:00 pm | Case Study: Proprietary I23 armed oncolytic

9:20 am | Panel: To IT or to IV? Intra-Tumoural vs Intra-Venous Administration

Dr Erik Digman Wiklund
Chief Business Officer
Targovax ASA

Erik trained as a scientist specializing in cancer epigenetics research, and holds a PhD in molecular biology. After completing a postdoctoral fellowship, he transitioned to management consulting and joined the Pharma and Healthcare practice of McKinsey & Company. For the past 5 years he has held several positions in Norwegian biotech companies, including at Algeta, which developed and launched Xofigo in 2014. He joined Targovax as CFO in 2017, and transitioned into the CBO position in 2018.

Day One

Thursday 13th December 2018

2:20 pm | Targovax’s ONCOS-102 in the Treatment of PD-1 Refractory Melanoma

8:40 am | Panel: One Vision for the Future of Oncolytic Virotherapies

Michael Moore
Vice President Investor Relations and Corporate Communications
Oncolytics Biotech

Experienced strategic communications and investor relations professional with a proven track record in designing and executing corporate communications and investor relations programs, nationally and internationally. Career spanning NASDAQ, NSYE and TSX listed companies focused on life sciences. Strong team leader with proven project management and interpersonal skills.

Day One

Thursday 13th December 2018

9:20 am | Panel: To IT or to IV? Intra-Tumoural vs Intra-Venous Administration

David Sherris
President and Chief Executive Officer
GenAdam Therapeutics Inc.

Experienced Chief Executive Officer with a demonstrated history of working in the biotechnology industry. Skilled in Protein Chemistry, Life Sciences, Business Development, Entrepreneurship, and Strategic Planning. Strong business development professional graduated from School. Dr. Sherris has been a successful serial entrepreneur developing biotechnology companies from the ground up, devising corporate strategy, enacting programs and carrying companies through funding and acquisition. Dr. Sherris prides himself as a “roll up your sleeves” CEO, entrepreneur, business development officer, drug developer and scientist, not simply a delegator. Dr. Sherris has worked with venture capital companies where he has both advised and raised finances for biotech companies. Dr. Sherris has been employed by pharmaceutical and biotechnology companies to manage external (academic groups and contract research organizations) and internal (directly manage, augment and expand internal scientific programs) research and development. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas. Dr. Sherris has held positions of increasing responsibility in public and private companies. Dr. Sherris has developed drugs from the bench to the clinic, partnered technologies to pharmaceutical companies and raised capital for companies at the triple digit million dollar levels.

Day One

Thursday 13th December 2018

3:50 pm | Panel: Viral Vehicle Comparison

Louis Cantolupo
Chief Operating Officer
Unleash Immuno Oncolytics

Action-oriented, hands-on biotech executive comfortable working in areas where the unknowns outweigh known comfort zones. Experienced in identifying novel opportunities by positioning (or repositioning) new and existing technology platforms, evaluating assets to ensure what's promised is what's delivered, and advancing early stage programs from the lab to partners. Specialties: oncolytic vectors, vaccines, gene therapeutics, monoclonal antibodies, cell-based technologies, discovery platforms; licensing, partnering, and business development; market and competitive analysis, preclinical development

Day Two

Thursday 13th December 2018

12:40 pm | Panel: The Case For and Against Internalizing the Manufacturing Process

Christophe Quéva
Chief Scientific Officer
Oncorus

Christophe Quéva, Ph.D., is Chief Scientific Officer and Senior Vice President, Research. Christophe is responsible for directing and advancing the company’s development program based on its next-generation immunotherapy platform of oncolytic viruses. An industry veteran, Christophe has nearly two decades’ immuno-oncology experience and successful portfolio-building track record from target identification and development through regulatory approval. Prior to joining Oncorus, Christophe was Chief Scientific Officer at iTeos Therapeutics where his responsibilities included leading the generation of an innovative immuno-oncology portfolio of small molecule and antibody programs and overseeing the company’s translational medicine strategy for its A2A antagonist and TIGIT programs. Before iTeos, he held successive senior positions at AstraZeneca, Amgen and Gilead Sciences where he led or supported drug discovery programs for oncology and inflammatory diseases, from target selection to commercial approval for small molecules and biologics. A holder of five patents and widely published, Christophe trained as a post-doctoral fellow at the Fred Hutchinson Cancer Research Center in Seattle after receiving his Ph.D. in Life and Health Sciences from the University of Lille, France.

Day One

Thursday 13th December 2018

9:20 am | Panel: To IT or to IV? Intra-Tumoural vs Intra-Venous Administration

Sridhar Pennathur
Senior Director and Fellow Biopharmaceutical Development
AstraZeneca

Sridhar Pennathur is Senior Director in the Biopharmaceutical Development group at AstraZeneca-Biologics and has over thirty years of experience in the biotech/pharma industry. He has worn many different hats while working at AstraZeneca-Biologics including roles in Quality Assurance, Quality Control, Manufacturing and Technical Operations. He has a Ph.D. in Virology and his thesis was focused on vaccinia virus. He also worked at Bristol-Myers Squibb where he published about twenty peer reviewed papers on the use of vaccinia virus as a viral vaccine vector. He is recognized as a subject matter expert in virology at AstraZeneca-Biologicals

Day One

Thursday 13th December 2018

3:50 pm | Panel: Viral Vehicle Comparison

11:50 am | Case Study: Considerations When Using Vaccinia Virus as a Vector for Oncolytic Vaccines

Dr John Goldberg
Senior Vice President Clinical Development and Practicing Paediatric Oncologist
Oncorus

John Goldberg is the Senior Vice President of Clinical Development at Oncorus, Inc. a Cambridge, MA based oncolytic virus therapy company advancing both intratumoral and systemic approaches. A practicing pediatric oncologist, Dr. Goldberg previously led the pediatric oncology phase 1 clinical trials program at the University of Miami prior to joining industry. In Miami, he led studies in children and adults using a variety of modalities including cellular and targeted therapy, and treated patients with leukemia, brain tumors and sarcoma. He made the leap to biotech to help bring a seasoned clinical perspective to drug development, and has developed immunotherapy and RNA targeted treatments subsequently. Responsible for all of clinical development at Oncorus, Dr. Goldberg is passionate about bringing new therapies to patients with unmet medical needs, including children with difficult to treat cancers.

Brian Haines PhD
Senior Director Pharmacology and Toxicology
Oncorus

Dr. Haines currently serves as the Sr. Director of Pharmacology and Toxicology at Oncorus, where he leads a group of molecular biologists, pharmacologists, and immunologists who investigate the preclinical activity, mechanisms of action, and safety of Oncorus’ OV candidates, toward advancement to the clinic. Before Oncorus, Dr. Haines supported or led the nonclinical pharmacology efforts at Merck (MSD) for many traditional small molecule oncology and immuno-oncology (IO) programs, including the pembrolizumab (Keytruda) PD-1 program, other immune checkpoint targets, as well as several small molecule IO and OV programs. Dr. Haines received his PhD in Immunology at Tufts University, and did his postdoctoral research in T cell genetics at M.I.T.

Day One

Thursday 13th December 2018

12:10 pm | Case Study: The Benefits of Monotherapies and Combination Based on Disease Indication

Lorena Lerner
Vice President Molecular Biology and Virology
Oncorus

Lorena Lerner Ph.D. is the Vice President, Molecular Biology & Virology at Oncorus, where she is leading the engineering of the next-generation immunotherapy platform of oncolytic viral vectors for the treatment of solid tumors. Lorena is an experienced cancer biologist with a proven track record of managing and advancing projects, from early discovery into clinical development. Most recently, Lorena served as Director of Biology at Quiet Therapeutics, where she was responsible for leading the development of a proprietary nanotechnology platform, identifying potent immunotherapy target candidates and optimizing vector design. Prior to Quiet, she served as Director of Target Discovery at Scholar Rock and held positions of increasing responsibilities at AVEO Oncology, where she pioneered and executed the development of AV-380, a cancer cachexia program targeting GDF15, from target identification, validation, and antibody discovery through preclinical development and out-licensing enterprises. Lorena received an MSc in Molecular Biology and a Ph.D. in Biochemistry from the University of Buenos Aires. She completed a post-doctoral research fellowship in Molecular and Cellular Biology with Professor James E. Darnell at Rockefeller University. Her academic training focused on the field of gene regulation and cancer metabolism and Immuno-oncology.

Day One

Thursday 13th December 2018

8:40 am | Panel: One Vision for the Future of Oncolytic Virotherapies

Beatriz Mesa
Senior Director Oncolytic Virus Manufacturing
Sorrento Therapeutics

Beatriz has spent the last 25+ years contributing to clinical and commercial manufacturing efforts on a diverse catalog of products including monoclonal antibodies, peptibodies and viral drug substances and drug products.  She has led manufacturing and process development teams at Amgen, provided manufacturing support at MilliporeSigma, and currently directs oncolytic virus manufacturing at Sorrento Therapeutics (San Diego, CA) where she has recently established a new clinical manufacturing facility, process development team, and GMP manufacturing team to supply upcoming Phase I and Phase II clinical trials.

Day Two

Thursday 13th December 2018

12:40 pm | Panel: The Case For and Against Internalizing the Manufacturing Process

Steve Thorne
Chief Scientific Officer
Western Oncolytics

Cancer immunotherapy expert, with over 15 years research and leadership experience in pre-clinical and translational development of novel cancer immunotherapies including immune cell based therapies, oncolytic viral therapies and gene therapy. Expert in immunocompetent mouse cancer models and non-invasive molecular imaging in animal models. Experience in process development for complex biological therapies and development of immune monitoring and immune assays.

Day Two

Thursday 13th December 2018

12:40 pm | Panel: The Case For and Against Internalizing the Manufacturing Process

12:10 pm | Case Study: Manufacturing Vaccinia Virus on a Commercial Scale

Shara Dellatore
Principal Scientist and Group Leader
Merck

• Ph.D. with experience in complex product characterization of monoclonal antibodies and therapeutic protein products • Team-oriented leader with experience working on multiple cross-functional biologic project development teams • Pepole manager of 9 junior and senior level scientists. Responsiblities include glycan, capillary electrophoresis, HPLC/UPLC assay method development and testing support for biologics products. • Developed and implemented extended characterization strategy to support Phase I and Phase III IND submissions • Author and reviewer of FDA regulatory submissions and associated supporting technical reports and memos • Experience with quality by design (QbD) and leader of critical quality attribute (CQA) team.

Day One

Thursday 13th December 2018

3:50 pm | Panel: Viral Vehicle Comparison

8:40 am | Panel: One Vision for the Future of Oncolytic Virotherapies

Angelica Loskog
CEO
Lokon Pharma

I am CEO of Lokon Pharma AB commercializing cancer immunotherapy invented at my lab at Uppsala University in Sweden. I am adjunct as full Professor of Immunotherapy at Uppsala University. I work as an advisor to the Swedish venture capital company Nxt2b AB, which also owns Lokon Pharma AB. I am member, or chairman, of the board of several companies within the Nxt2b corporation such as Lokon, Vivolux, RePos Pharma, Bioimics and Hansa Medical.

Day Two

Thursday 13th December 2018

10:10 am | Case Study: LOAd703 Virus in Pancreatic Cancer Clinical Trial

Maritza McIntyre
Former Chief Gene Therapy Branch
FDA

Dr. McIntyre provides strategic regulatory and product development advice to biotech companies, academics, and venture capital firms. With 20 years’ experience in the development, evaluation and regulation of biological and small molecule products within startup biotech, FDA, and consulting, she has proven success in defining regulatory strategies for products with complex regulatory challenges. She has multidisciplinary experience, including CMC, preclinical, and clinical with a wide range of product types, including gene and cell therapy products, prophylactic and therapeutic vaccines, biological products and small molecules at varied stages of product development.

Day Two

Thursday 13th December 2018

11:10 am | Non-Clinical Safety Studies